Innate lymphoid cells (ILCs) have potent immunological functions in experimental conditions in mice, but their contributions to immunity in natural conditions in humans have remained unclear. We investigated the presence of ILCs in a cohort of patients with severe combined immunodeficiency (SCID). All ILC subsets were absent in patients with SCID who had mutation of the gene encoding the common g-chain cytokine receptor subunit IL-2Rg or the gene encoding the tyrosine kinase JAK3. T cell reconstitution was observed in patients with SCID after hematopoietic stem cell transplantation (HSCT), but the patients still had considerably fewer ILCs in the absence of myeloablation than did healthy control subjects, with the exception of rare cases of reconstitution of the ILC1 subset of ILCs. Notably, the ILC deficiencies observed were not associated with any particular susceptibility to disease, with follow-up extending from 7 years to 39 years after HSCT. We thus report here selective ILC deficiency in humans and show that ILCs might be dispensable in natural conditions, if T cells are present and B cell function is preserved.
ILCs include natural killer (NK) cells and three other main subsets, ILC1, ILC2 and ILC3, referred as to 'helper-like ILCs' [1] [2] [3] . Since their discovery, ILCs have been shown to contribute to wound healing and defense against infection, and studies have revealed critical aspects of their differentiation. However, much of the role of ILCs remains to be elucidated, particularly given the diversity of these cells, which adds to the complexity of their analysis.
Unlike T cells and B cells, ILCs do not express antigen-specific receptors derived from gene rearrangements dependent on RAG recombinases. Other than that major difference in their recognition repertoire, the ILC and T cell subsets display striking similarities, as ILC1s, ILC2s and ILC3s are driven by the transcription factors T-bet, GATA-3 and RORγt, respectively, and produce the cytokines IFN-γ (ILC1s), interleukin 5 (IL-5) and IL-13 (ILC2s), and IL-17 and IL-22 (ILC3s) [1] [2] [3] . In addition, NK cells are driven by the transcription factors Eomes and T-bet, can be cytolytic and produce interferon-γ (IFN-γ), like CD8 + T cells. Such similarity of features has led to the suggestion that ILCs are the innate counterparts of T cells [1] [2] [3] . During the course of evolution, two highly parallel systems have thus emerged, with ILCs mimicking the effector profile of T cell subsets. However, it remains unclear how these two systems are integrated in natural conditions in humans.
In mice, all ILCs are generated by a transcription-factor-Id2dependent pathway from a common lymphoid progenitor, which initially differentiates into a common ILC precursor. The common ILC precursors differentiate into three precursors and give rise to three different lineages: NK-cell precursors, lymphoid-tissue-inducercell precursors, and common-helper-innate-lymphoid-cell precursors. Common-helper-innate-lymphoid-cell precursors express the transcription factor PLZF and give rise to the ILC1, ILC2 and ILC3 subsets. Lymphoid-tissue-inducer cells are essential for the development of secondary lymphoid organs, such as lymph nodes and Peyer's patches in mice. In contrast, ILC differentiation in humans is less well understood 4 . NK-cell progenitors with a Lin − CD34 + CD38 + CD123 − CD45RA + CD7 + CD10 + CD127 − phenotype have been found in the bone marrow, cord blood and tonsils 5 . These cells differentiate exclusively into NK cells and are unable to generate ILC2, ILC3 or other lineages. ILC3 progenitors have been identified in human tonsils 1 2 9 2 VOLUME 17 NUMBER 11 NOVEMBER 2016 nature immunology A r t i c l e s and intestinal lamina propria but not in the bone marrow, thymus or peripheral blood 6 . A Lin − CD34 + CD45RA + CD117 + IL-1R1 + RORγt + progenitor population expressing Id2 has been shown to give rise in vitro to all ILCs, including NK cells, but not other leukocyte lineages 7 . This RORγt + progenitor is present selectively in the tonsils, lymph nodes and spleen but not in the peripheral blood, bone marrow, umbilical cord blood or thymus 7 . SCID is a life-threatening condition that affects infants and is characterized by defective T cell development associated with various deficiencies of other cell lineages, such as NK cells, B cells and myeloid cells 8, 9 . Patients present with profound abnormalities in immunity that lead to severe recurrent and fatal infections. The life-threatening nature of SCID requires treatment by allogeneic HSCT or gene therapy to resolve the immunodeficiency syndrome [9] [10] [11] . HSCT often requires that the patients be treated with a conditioning regimen to induce myeloablation and hence favors engraftment. Some patients with SCID who have mutation of IL2RG or autosomal-recessive mutation of JAK3. Both these types of mutation result in a complete block in the development of T cells and NK cells 12 . We delineated here the differentiation and function of human ILCs by analyzing these cells in patients with SCID resulting from mutation of IL2RG or JAK3, before and after treatment by allogeneic HSCT. We found that these patients were ILC deficient before HSCT and continued to display ILC deficiency after HSCT in the absence of myeloablation. No particular susceptibility to disease was observed in these patients. Together with published findings of mice 13, 14 , these results provide evidence for possible redundancy of the protective immunological function of ILCs in the presence of a functional adaptive immune system.
RESULTS

Circulating ILCs in healthy children and adults
The ILC1, ILC2 and ILC3 subsets are present mainly as sedentary cells in tissues, in which they can be maintained by self-renewal 15 . Nevertheless, cells of these ILC subsets are detectable in human peripheral blood [16] [17] [18] . Using a panel of conventional lineage markers (lineage (Lin): CD3, CD19, CD14, TCRαβ, TCRγδ, CD94, CD16, FcεRI, CD34, CD123 and CD303) and cell-surface expression of CD127, CD117 and CRTH2, we identified the ILC1 subset as Lin − CD127 + CD117 − CRTH2 − cells, the ILC2 subset as Lin − CD127 + CRTH2 + cells and the ILC3 subset as Lin − CD127 + CD117 + CRTH2 − cells, among the circulating lymphocytes. NK cells were classically defined as CD3 − CD56 + lymphocytes ( Fig. 1a) . All ILC subsets were detected in the peripheral blood of healthy children (6-18 years) and adults ( Fig. 1b,c , Table 1 and Supplementary Table 1 ). NK cells were by far the most abundant circulating ILCs (with a median of 215 × 10 3 cells per ml in healthy children and 265 × 10 3 cells per ml in adults); the total number of ILCs was only 3.8 × 10 3 cells per ml in healthy children and 1.6 × 10 3 cells per ml in adults ( Fig. 1b,c , Table 1 and Supplementary Table 1 ). The number and frequency of helper-like ILCs among peripheral blood lymphocytes decreased with age ( Fig. 1b) , whereas this trend was not observed for NK cells (Fig. 1c) . We also investigated whether there was any association between the number of circulating ILC1s and that of circulating ILC2s or ILC3s in healthy subjects and whether there was an effect of the subject's sex on these values. In accordance with the common origin of helper-like ILCs, there was a strong positive correlation between the absolute number of ILC2s and that of ILC3s in children and adults and there was a weak or moderate positive relationship for ILC1s and other ILCs (Supplementary Fig. 1 ). However, there was no difference related to the subjects' sex (data not shown). Consistent with the greater number of ILCs in children, the abundance of ILCs was greater in umbilical cord blood than in the peripheral blood of children or adults (Fig. 1d) . The ILC1, ILC2 and ILC3 subsets in the circulation or cord blood displayed an equivalent frequency of total helper-like ILCs, and this distribution remained stable across age groups (Fig. 1e) . Together, these results established normal values for human circulating ILCs under natural conditions that were consistent with those reported previously for adults 19 , and they paved the way for comparisons with data of circulating ILCs for patients with various pathological conditions.
Lack of circulating ILCs in SCID with JAK3 deficiency
The ILC1, ILC2 and ILC3 subsets are dependent on IL-7, whereas NK cells are dependent on IL- 15 (ref. 20) . The IL-7 and IL-15 signals are integrated via IL-2Rγ and JAK3. NK-cell deficiency is a known hallmark of typical cases of deficiency in IL-2Rγ or JAK3 (ref. 12) . We therefore assessed the presence of other ILCs in patients with SCID who had genetic deficiency in this pathway. Our cohort comprised 28 patients with SCID (12 deficient in IL-2Rγ, 9 deficient in JAK3, and 7 deficient in RAG1 or RAG2) and 6 control subjects ( Table 2 and Supplementary Table 1 ). Among these 28 patients with SCID, we were able to monitor circulating ILCs before HSCT in 5 patients and after HSCT in 20 patients ( Table 2 and Supplementary Table 1 ). Before HSCT, no circulating ILCs were detected in the peripheral blood of three of patients with SCID who had JAK3 deficiency (patients P19, P20 and P21) ( Fig. 2) . These data were consistent with the absence of tonsils and palpable lymph nodes shown before in patients with SCID 8, 21, 22 and suggested an absence of the lymphoid-tissue-inducer subset of ILCs in patients with this condition. In contrast, the ILC compartment was phenotypically normal in patients with RAG1 deficiency (patients C11 and C12) ( Supplementary Fig. 2) , consistent with the lack of a requirement for RAG-dependent DNA-recombination events in the development of ILCs in mice 2,3,23-25 .
ILC deficiency in SCID treated with non-myeloablative HSCT We studied patients with SCID who were deficient in IL-2Rγc or JAK3 (n = 18; P1-P18) and had undergone HSCT 7-39 years before the ILC analysis, with mild myeloablation or no myeloablation (except for P4), and analyzed the reconstitution of ILCs in these patients ( Table 2 and Supplementary Table 1 ). This cohort consisted of 7 children (P1-P7) and 11 adults (P8-P18) with mutation of IL2RG (12 patients) or JAK3 (6 patients). We also analyzed circulating or tissue-resident ILCs in 6 patients with SCID who had mutation of RAG1 or RAG2 that resulted in selective impairment in the development of T cells and B cells and who underwent HSCT after myeloablation (C1, C2, C10, C11 and C13). T cell reconstitution was observed in both groups of patients 26 (Fig. 3) . In almost all patients with SCID of the first group who underwent HSCT without myeloablation, our analysis Frequency of NK cells in the lymphocyte gate, frequency of ILC subsets in the ILC gate, and absolute number of NK cells (per µl) and ILC subsets (per ml) in the peripheral blood of healthy children (n = 29) and adults (n = 30), compiled from flow cytometry as in Figure 1 and presented as median values (10th and 90th percentiles in parentheses). Data are representative of one experiment per donor. Characteristics of pediatric (P1-P7) and adult (P8-P18) patients with SCID, and patients with complete donor chimerism (C1-C13), for whom ILCs were evaluated after grafting; C12, P19, P20 and P21 are not included here because their ILCs were evaluated only before transplantation. Patients were diagnosed as having mutation of IL2RG (γC), JAK3 (JAK3), RAG1 (RAG1) or RAG2 (RAG2), or acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML) or severe aplastic anemia (SAA). Donor origins of the transplanted tissue include mismatched-related donor (MMRD), 'pheno-related donor' (PRD; related donor with more than one compatible HLA haplotype but not genetically identical), umbilical cord blood from an unrelated donor (UUCB), matched unrelated donor (MUD) or matched sibling donor (MSD). Conditioning regimens provided before transplantation included no conditioning (0), busulfan (BU; mg per kg body weight (total dose)), cyclophosphamide (Cy; mg per kg body weight (total dose)), fludarabine (Flu; mg per m 2 of skin (total dose)), total body irradiation (TBI) or thiotepa (TT). Patient samples also underwent depletion of T cells via positive selection of CD34 + cells (CD34 pos) or negative selection by mAb (mAb), or E-rosetting (E-ros), or no depletion of T cells (0). The final chimerism is defined as donor chimerism (1), host myeloid chimerism (2) or mixed myeloid chimerism (3). ND, not done; NA, not applicable (no lymphocyte reconstitution at chimerism evaluation).
A r t i c l e s revealed a highly specific split chimerism, with the T cells of donor origin and the other leukocyte subsets of host origin 27 ( Table 2 ).
In the patients with SCID who had mutation of RAG1 or RAG2, long-term analysis revealed complete donor chimerism ( Table 2) , which provided evidence of donor HSC engraftment. The ILC2 and ILC3 subsets were barely detectable in the peripheral blood of pediatric patients ( Fig. 3a) or adult patients ( Fig. 3b) with SCID who had mutation of IL2RG or JAK3 and were undergoing HSCT. Consistent with published studies 26 , circulating NK cells were either undetectable or present in only very low numbers in all of these patients ( Fig. 3) . Similarly, ILC1s were generally undetectable, but a small number of ILC1s were present in a few children and adults ( Fig. 3) . However, a large number of ILC1s were present in one child who was otherwise healthy (P1) and one adult with chronic lung infections (P12) ( Fig. 3) . Human ILC1s are highly heterogeneous, and published findings indicate that ILC1s include cells that synthesize transcripts encoding variable regions of the T cell antigen receptor 28, 29 and other molecules typically expressed by T cells, such as CD4, CD5, CD6, CD28 and CD27 (refs. 29, 30) . Indeed, most of the ILC1s in HSCT-treated patients with SCID and healthy control subjects were CD5 + (Supplementary Fig. 3) . These results suggested that a substantial fraction of these ILC1s might have belonged to the T cell lineage and that the number of true ILC1s that reconstituted HSCT-treated patients with SCID might have been even lower than that estimated by the classic Lin − CD127 + CD117 − CRTH2 − cell-surface-phenotype analysis. Nevertheless, our results showed that patients with SCID who had mutation of IL2RG or JAK3 continued to display ILC deficiency after HSCT in the absence of myeloablation. One obvious limitation of the analysis above was the lack of data on tissue-resident ILCs. We obtained skin and gut biopsies from patients with SCID who had mutation of IL2RG or JAK3 and were treated with non-myeloablative HSCT (patients P1, P3, P5, P11, P14 and P16) and generated paraffin-embedded and frozen tissue sections from the biopsies ( Table 2) . With the exception of the biopsies of P3, these biopsies were performed 1-10 years after HSCT. We assessed the presence of all NKp46 + cell subsets of ILCs (i.e., NK cells 2 , tissue-resident CD127 − ILC1s 31 and NCR + ILC3s 2 ) in these samples on the basis of positive staining for the activating receptor NKp46 and an absence of expression of the invariant signaling protein CD3ε. This analysis was made possible by the generation of a monoclonal antibody to human NKp46 screened for its reactivity to paraffin-embedded tissues. In these tissues, NKp46 + ILCs were not detected or were barely detectable in three of the patients we assessed (Fig. 4a) . We also analyzed frozen sections of gut biopsies from two patients (P1 and P3); in P3, T cells (CD3 + ) were detected but no cell-associated NKp46 staining was detectable, in contrast to the results obtained for control sections (Supplementary Fig. 4) .
We also sought to analyze ILC2s in tissue sections corresponding to those assessed for NKp46 + ILCs. However, the consensus marker for ILC2s, CRTH2, could not be used for analysis of tissue sections due to the lack of reliable reagent. An alternative involved reliance on immunofluorescence staining based on the CD3 − CD11b − ICOS + ST2 + and HC  P1  P2  P3  P4  P5  P6  P7  C1  C2  C3  C4   HC  P8  P9  P10  P11  P12  P13  P14  P15  P16  P17 P18 C6 C7 C8 Figure 3 Long-term ILC lymphopenia in HSCT-treated patients with SCID. Absolute number of CD3 + T cells, CD19 + B cells and CD3 − CD56 + NK cells or ILC subsets in the peripheral blood of 6-to 14-year-old healthy control subjects (HC; n = 12), patients with SCID who have mutation of IL2RG or JAK3 (SCID; n = 7) and patients with complete donor chimerism (CDC; n = 5) (a) or of healthy adult control subjects (n = 26), adult patients with SCID who have mutation of IL2RG or JAK3 (n = 11) and adult patients with complete donor chimerism (n = 3). Lin − CD34 − ST2 + IL-17RB + KLRG1 + phenotypes, as described before 32 . However, the density of expression of the IL-33 receptor ST2 varies with ILC2 activation 33 ; therefore, ST2 expression did not seem as reliable as CRTH2 staining was for the identification of circulating ILC2s. We thus used the CD3 − CD11b − ICOS + phenotype to evaluate the presence of ILC2s in gut and skin. In these tissues, ILC2s were barely detectable in sections from patients with SCID who had mutation of IL2RG or JAK3 and were treated with non-myeloablative HSCT (Fig. 4d) . We drew similar conclusions by analysis of Lin − CD34 − KLRG1 + staining (data not shown). The specificity of our staining protocols was confirmed by the absence of detectable staining in tissues of cytopenic patients with SCID who had mutation of RAG1 (C11 and C13), obtained 3 months after failure of HSCT performed in myeloablative conditions (Supplementary Fig. 5 ). Thus, patients with SCID who had mutation of IL2RG or JAK3 were deficient in circulating and tissue-resident ILCs, and this deficiency persisted after non-myeloblative HSCT.
ILC reconstitution in myeloablative HSCT
A question that can be raised from the results reported above is whether ILC reconstitution might no longer happen in post-natal life in patients with mutation of IL2RG or JAK3. Only one patient with SCID in this study who had mutation of IL2RG underwent myeloablative HSCT (P4) ( Table 2 ). ILC reconstitution was not observed in the peripheral blood of this patient (P4) (Fig. 3a) , which indicated that if myeloablation were one of the factors involved in the reconstitution of circulating ILCs in HSCT-treated patients with SCID, it was not the only parameter. However, partial tissue-resident reconstitution of ILCs was observed in patients treated with HSCT under mild myeloablative conditions (results for patient P15 presented here; Fig. 4c ). We also analyzed long-term reconstitution (>4 years) of all subsets of circulating ILCs in patients undergoing myeloablative HSCT for acute lymphoblastic leukemia (n = 3), acute myelogenous leukemia (n = 1), aplastic anemia (n = 2) or SCID with RAG1 mutation (n = 2). All these patients displayed complete donor chimerism ( Table 2) . In these settings, NK cells, ILC1s, ILC2s and ILC3s were detected (Fig. 3) .
The number of these cells in blood was heterogeneous, particularly for ILC1s ( Fig. 3) . For ILC2s and ILC3s, the number of cells in the blood was lower than that of age-matched controls for the pediatric patients ( Fig. 3a) but was normal (ILC2) or close to normal (ILC3) in adults (Fig. 3b) . As expected, complete reconstitution of NK cells was observed in pediatric and adult patients ( Fig. 3) . Thus, long-term reconstitution of circulating ILCs after HSCT was observed in these myeloablative conditions. In addition, NKp46 + ILCs and ILC2s were readily observed in tissues from patients treated with myeloablative HSCT, as illustrated by the analysis of skin biopsies from a patient with SCID who had mutation of RAG2 (C10) and was treated with myeloablative HSCT (Fig. 4b,d) . Thus, ILCs were reconstituted postnatally. Therefore, ILC reconstitution occurred in humans after the transplantation of allogeneic hematopoietic grafts, but these cells developed only in myeloablative conditions. As a control, tissue-resident gut ILCs were observed in a patient with SCID who had mutation of RAG1 (C9) but was treated with 'pheno-related' HSCT (related donor with more than one compatible HLA haplotype but not genetically identical) under non-myeloablative conditions (Fig. 4b,d ). Our data also showed that the precursors of all ILC subsets were present in human bone marrow and cord blood, the two sources of hematopoietic cells used for HSCT for the patients with SCID in our cohort ( Table 2) .
ILC reconstitution in mouse HSCT
To further ascertain the lack of tissue-infiltrating ILCs in HSCT-treated patients, we used mouse models to mimic HSCT in myeloablative and non-myeloablative conditions. CD45.2 + bone marrow LSK (Lin − Sca1 + cKit + ) progenitors were sorted as both Flt3 int multipotent progenitors and as Flt3 + lymphoid-primed multipotent progenitors (Supplementary Fig. 6a ) and were injected into sub-lethally irradiated or non-irradiated alymphoid CD45.1 + Rag2 −/− Il2rg −/− mice. At 3 weeks after HSCT, ILC populations from the liver, lungs and intestine of the recipient mice were analyzed. Lung ILC2 (Lin − Gata3 + CD127 + ICOS + ST2 + ) populations were observed in all irradiated mice but were undetectable in all non-irradiated mice ( Fig. 5 and Supplementary Fig. 6b) . Fig. 5  and Supplementary Fig. 6c ). Thus, reconstitution of ILC2s and ILC3s was effective in all sub-lethally irradiated recipients but not in nonirradiated recipient mice. The reconstitution was much more effective for ILC1s and NK cells than for ILC2s or ILC3s in non-myeloablative conditions, as intestinal lamina propria ILC1s (Lin − NKp46 + NK1.1 + CD49a + CD49b − ) and NK cells (Lin − NKp46 + NK1.1 + CD49a − CD49b + ) of donor origin were equally present in both irradiated mice and non-irradiated mice ( Fig. 5 and Supplementary Fig. 6c ). Although liver ILC1s (Lin − NKp46 + NK1.1 + CD49a + CD49b − ) were detected in irradiated mice, they were lower in abundance in non-myeloablative conditions ( Fig. 5 and Supplementary Fig. 6d) . Similarly, lung NK cells (Lin − NKp46 + NK1.1 + CD127 − ) underwent reconstitution in non-myeloablative conditions, but this was not as efficient as their reconstitution in irradiated mice ( Fig. 5 and Supplementary Fig. 6b) . Nonetheless, circulating NK cells (Lin − NKp46 + NK1.1 + CD49a − CD49b + ) were detected in the recipient mice reconstituted in Table 3 Clinical follow-up Figure 5 Reconstitution of ILCs after engraftment of adult multipotent progenitor cells into Rag2 −/− Il2rg −/− mice. Absolute number of cells in various ILC populations (horizontal axes) in the liver, lungs and small intestine (SI) of irradiated and non-irradiated (key) Rag2 −/− Il2rg −/− (CD45.1 + ) recipient mice reconstituted with multipotent progenitors sorted (as in Supplementary Fig. 6 ) from the bone marrow of C57BL/6/J (CD45.2 + ) adult donor mice, analyzed by flow cytometry: donor-derived (CD45.2 + ) hematopoietic populations were separated from their host (CD45.1 + ) counterparts through the use of the congenic markers CD45.1 and CD45.2; ILC1s and NK cells from the lungs were identified as NKp46 + NK1.1 + IL-7Rα + and NKp46 + NK1.1 + IL-7Rα − , respectively; ILC2s from the lungs were identified as Lin − Gata3 + IL-7Rα + cells co-expressing ICOS and ST2; ILC1s and NK cells from the liver were identified by expression of CD49a and CD49b, respectively, on NKp46 + NK1.1 + populations; NK cell, ILC1, ILC2 and ILC3 populations from the lamina propria of the small intestine (SILP) were identified by expression of CD3, CD19, Thy1, CD4, NKp46, NK1.1, CD49a, CD49b, KLRG1, RORγt, Gata3 and IL-7Rα. Each symbol represents an individual mouse. *P < 0.02 (Mann-Whitney test). Data are representative of two experiments with three mice per condition (mean and s.d.).
non-myeloablative conditions (data not shown), which indicated that the presence of ILCs in peripheral blood correlated with the presence of tissue-resident ILCs. The absence of ILC2 and ILC3 chimerism in nonmyeloablative conditions in these mice supported the data obtained for HSCT-treated patients with SCID and suggested an inability of common-helper-innate-lymphoid-cell precursors in humans and in mice to fully differentiate into the appropriate niches, as they might compete with endogenous progenitors in these niches. This mechanism for the restriction of donor HSC engraftment by occupancy of niches by host HSCs was supported by data showing that the clearance of HSC niches via antibody treatment leads to efficient transplantation 34 .
Human ILC deficiency is not associated with disease In HSCT-treated patients with SCID, we observed no increase, relative to normal values, in non-conventional T-cell subsets, such as γδ T cells or V α 24 + V β 11 + NKT cells that could compensate for the absence of ILCs on the basis of similarities in effector function ( Supplementary  Fig. 7a,b) . The almost total absence of ILCs in these patients thus provided us with a highly informative situation for evaluating the function of ILCs in natural conditions in humans. Notably, this situation of persistent ILC deficiency had no major clinical consequences over very long periods of follow-up (7-39 years) ( Table 3) . This cohort of patients was no more prone to infection or inflammation than were those undergoing HSCT for other types of SCID with or without myeloablation 26, 35 (Table 3) . Growth and quality of life were similar in these groups of patients ( Table 3) . A higher-than-normal incidence of infection with human papillomavirus leading to chronic disease has been observed in HSCT-treated patients with SCID who have mutation of IL2RG or JAK3 (ref. 36 ). However, no association was detected between infection with this virus and the absence of NK cells 36 or other ILCs (Table 3) . Instead, these data fit with the hypothesis that infection with this virus is controlled by IL-2Rγ-or JAK3-dependent signaling in keratinocytes rather than in lymphocytes 37, 38 . Nine patients with SCID in our cohort who had mutation of IL2RG or JAK3 required immunoglobulin replacement because of residual B cell deficiency due to impaired signaling via the cytokine receptors IL-21R and IL-4R in B cells with mutation of IL2RG or JAK3 (ref. 39) ( Table 3 ). The pattern of ILC detection in the blood was similar for these patients and for the other patients of the cohort ( Table 3) . ILCs thus seemed to be dispensable in humans with a functional adaptive immune system, which supported the proposal of redundancy between ILCs and adaptive lymphocytes in humans in natural conditions.
DISCUSSION
We aimed here to contribute to the understanding of ILC differentiation and function in humans in natural conditions. We focused our analysis on a cohort of patients with SCID who were deficient in T cells, B cells and NK cells and had deficiency in JAK3 or IL-2Rγ and showed that these patients lacked all ILC subsets. These results are consistent with the strict dependence of ILC1s, ILC2s, ILC3s and NK cells on IL-7 or IL- 15 (refs. 40-42) .
The patients in our cohort with SCID and mutation of JAK3 or IL2RG underwent allogeneic HSCT, which could be performed in the absence of myeloablation due to the absence of allogeneic immune responses in the recipients. In these HSCT protocols, split chimerism was generally observed, with development of T cells from the transplanted donor cells and the other lineages remaining of host origin 27 . Progenitor T cells are thought to persist in the long term in the absence of donor HSC engraftment 27, 43 . In this setting, no reconstitution of blood NK cells, ILC2s or ILC3s was observed. In tissues, a marked reduction in the abundance of NKp46 + ILCs and ILC2 was also observed. Thus, patients with SCID who had mutation of IL2RG or JAK3 continued to display ILC deficiency after HSCT in the absence of myeloablation. However, there was a trend for a better reconstitution of the ILC1 subset that even expanded in a few patients (2 of 18 patients in our study). Among the ILC subsets, the ILC1 subset is still not well defined. In particular, it is possible that some of these ILC1s might correspond to activated T cells with low expression of the complex of CD3 invariant signaling proteins and the T cell antigen receptor. The cell-surface expression of not only CD5 but also CD4, CD28 and CD3 and expression of transcripts encoding the T cell antigen receptor is consistent with this hypothesis [28] [29] [30] . The lack of a robust consensual definition of ILC1 phenotype is most probably one of the factors that leads to the apparent heterogeneity of ILC1s.
In contrast to the results reported above, circulating and tissue ILCs were detected in most patients of our cohort who underwent HSCT with myeloablation, consistent with published reports showing an early wave of NK cells 44 and slow, incomplete helper-like ILC reconstitution 16 in these settings. The partial nature of the reconstitution of circulating ILCs in these patients makes it impossible to rule out the possibility that ILC precursors or differentiated ILCs seed various anatomical sites throughout the body during embryonic development, with subsequent maintenance by self-renewal in situ, which would contribute to the production of tissue-resident ILCs after birth 15, 45 . In this hypothesis, ILCs could have the following two distinct anatomical and temporal origins: yet-to-be-identified organs during embryonic life; and bone marrow after birth and in stress conditions such as HSCT. This 'dual-ILC' system would parallel the observation of the layered system composed of tissue-resident macrophages that originate mainly from yolk-sac progenitor cells and of macrophages that originate from bone-marrow hematopoietic stem cells 46 . Nevertheless, our data indicated that ILCs can be reconstituted postnatally. Those data were supported by similar results obtained in our mouse model of HSCT.
ILCs are seen as sentinels and local guardians of tissue function, and many immunological functions have been attributed to them, mostly on the basis of experimental challenges in mice or in vitro experiments with human cells 1 . However, the small number of genes selectively expressed by ILCs or ILC subsets 28 and the consequent lack of mouse models with selective targeting of ILC subsets has hindered attempts to delineate the selective contribution of these cells to immunological defense in vivo 47 . The much lower abundance of subsets of circulating and tissue-resident ILCs in transplanted patients with SCID with mutation of IL2RG or JAK3, with the exception of rare cases of ILC1 reconstitution, has provided an informative model with which to assess the role of ILCs in natural conditions in humans. It was clear from our study that these major ILC deficiencies appeared to be clinically silent, in contrast to the severe clinical conditions associated with deficiency in T cells and B cells. Thus, ILCs appear to be redundant, at least in the context of modern medicine and hygiene, which provides an alternative view of their immunological function. Further very long-term evaluation, beyond 40 years, will nevertheless be needed to determine whether redundancy of T cells, NK cells and ILCs is maintained in older patients. Our findings are supported by the redundancy of ILC3s and T cells in protection against intestinal infection of mice with Citrobacter rodentium 13, 14 . They are also consistent with case reports of impaired NK-cell effector function without apparent clinical immunodeficiency in humans 48 . Notably, NK cells have been shown to contribute to tumor immunosurveillance; however, our cohort was too small to address this possibility. Given the similarities between ILCs and T cells in terms of transcription-factor expression, cytokine secretion and localization, ILCs are probably 'substituted' 1 2 9 8 VOLUME 17 NUMBER 11 NOVEMBER 2016 nature immunology A r t i c l e s by T cells rather than by B cells. Redundant mechanisms that ensure a robust immune response might have led to the selection of features common to ILCs and T cells. Our data indicating that ILCs are part of a multi-layered protective arsenal of immune cells suggest that it would be useful to elucidate the role of ILCs in patients with various genetic or acquired conditions that compromise adaptive immunity, including patients on immunosuppressive therapy. Depletion of circulating ILCs has been reported in patients infected with human immunodeficiency virus who are not receiving early antiretroviral therapy, but the effect of this lack of ILCs on immunodeficiency and the underlying mechanisms remain unknown 19 . Further investigation of the role of ILCs in these conditions, as well as during embryonic life, early childhood and old age, will be essential for full understanding of ILC biology. ILCs have also been shown to have a role in reproduction. Indeed, the uterine ILC population, including NK cells, expands during pregnancy, and these cells have been reported to regulate placental development and fetal growth in humans and mice 49 . However, two female JAK3-deficient patients included in our study had no signs of fertility disorders and had healthy babies with a normal birth weight and no other pathological symptoms following pregnancies free of adverse clinical events. Therefore, ILCs seem to be dispensable for human reproduction in natural conditions.
METHODS
Methods and any associated references are available in the online version of the paper.
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